Eribulin in Metastatic Breast Cancer: Actual Clinical Practice
A. V. Sultanbaev,
K. V. Menshikov,
Sh. I. Musin,
I. A. Menshikova,
N. I. Sultanbaeva,
E. V. Popova,
V. E. Askarov https://doi.org/10.24060/2076-3093-2023-13-1-77-86
Abstract
Breast cancer is the most common cancer in women, both in the Russian Federation and in the United States. Eribulin is a new microtubule inhibitor, used in the USA, Europe and other countries around the world to treat patients with advanced or metastatic breast cancer, resistant to other lines of therapy. Eribulin mesylate is a structurally simplified, synthetic analogue of halichondrin B, a substance derived from a marine sponge Halichondria okadai. The mechanism of action: eribulin inhibits the microtubule dynamics, binds to the plus ends of microtubules and inhibits microtubule growth in interphase cells, without affecting the shortening phase and tubulin sequesters into nonproductive aggregates, leading to G2/M cell-cycle block and eventual apoptotic cell death after prolonged mitotic blockage. A wide variety of patients with a number of comorbidities and lower functional status are treated in actual clinical practice. The reported data suggest that eribulin has demonstrated comparable results to the EMBRACE study for a wider and more diverse cohort of patients. Further studies of eribulin in actual clinical practice will certainly provide new opportunities for the treatment of metastatic breast cancer.
About the Authors
A. V. Sultanbaev
Republican Clinical Oncology Dispensary
Russian Federation
Russian Federation
Alexander V. Sultanbaev — Cand. Sci. (Med.), Anticancer Drug Therapy Unit
Ufa
K. V. Menshikov
Republican Clinical Oncology Dispensary; Bashkir State Medical University
Russian Federation
Russian Federation
Konstantin V. Menshikov — Cand. Sci. (Med.), Assoc. Prof., Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education, Chemotherapy Unit
Ufa
Sh. I. Musin
Republican Clinical Oncology Dispensary
Russian Federation
Russian Federation
Shamil I. Musin — Cand. Sci. (Med.), Surgery Unit No. 6
Ufa
I. A. Menshikova
Bashkir State Medical University
Russian Federation
Russian Federation
Irina A. Menshikova — Cand. Sci. (Med.), Assoc. Prof., Department of Biological Chemistry
Ufa
N. I. Sultanbaeva
Republican Clinical Oncology Dispensary
Russian Federation
Russian Federation
Nadezhda I. Sultanbaeva — Anticancer Drug Therapy Unit No. 1
Ufa
E. V. Popova
Republican Clinical Oncology Dispensary
Russian Federation
Russian Federation
Ekaterina V. Popova — Outpatient Antiсancer Drug Therapy Unit (Сhemotherapy)
Ufa
V. E. Askarov
Republican Clinical Oncology Dispensary
Russian Federation
Russian Federation
Vadim E. Askarov — Outpatient Antiсancer Drug Therapy Unit (Сhemotherapy)
Ufa
References
1. National Cancer Institute. SEER Cancer Statistics Factsheets: female breast cancer. [cited 2022 Oct 21]. Available from: http://seer.cancer.gov/statfacts/html/breast.html
2. Kawano S., Ito K., Yahata K., Kira K., Abe T., Akagi T., et al. A landmark in drug discovery based on complex natural product synthesis. Sci Rep. 2019;9(1):8656. DOI: 10.1038/s41598-019-45001-9
3. Dybdal-Hargreaves N.F., Risinger A.L., Mooberry S.L. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015;21(11):2445–52. DOI: 10.1158/1078-0432. CCR-14-3252
4. Halaven (eribulin mesylate) injection, for intravenous use [prescribing information]. Eisai Inc., 2016.
5. Wang X., Liu S., Xue Y. Treatment strategy and safety of Eribulin in advanced breast cancer. J Coll Physicians Surg Pak. 2022;32(1):122–4. DOI: 10.29271/jcpsp.2022.01.122. PMID: 34983165
6. O'Shaughnessy J., Kaklamani V., Kalinsky K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncol. 2019;15(14):1641–53. DOI: 10.2217/fon2018-0936
7. Halaven 0.44 mg/ml solution for injection [summary of product characteristics]. Hertfordshire: Eisai Europe Limited; 2017.
8. Pedersini R., di Mauro P., Amoroso V., Parati M.C., Turla A., Ghilardi M., et al. Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data. J Geriatr Oncol. 2020;11(6):976–81. DOI: 10.1016/j.jgo.2020.03.021
9. López González A., Del Barco Berrón S., Grau I., Galan M., Castelo Fernández B., Cortés A., et al. Challenging endocrine sensitivity of hormone receptor-positive/HER2-negative advanced breast cancer with the combination of eribulin and endocrine therapy: the REVERT study. Cancers (Basel). 2022;14(23):5880. DOI: 10.3390/cancers14235880
10. Pellegrino B., Cavanna L., Boggiani D., Zamagni C., Frassoldati A., Schirone A., et al. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO Open. 2021;6(1):100019. DOI: 10.1016/j.esmoop.2020.100019
11. Olatunde O.Z., Yong J., Lu C. The progress of the anticancer agents related to the microtubules target. Mini Rev Med Chem. 2020;20(20):2165–92. DOI: 10.2174/1389557520666200729162510
12. Okouneva T., Azarenko O., Wilson L., Littlefield B.A., Jordan M.A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 2008;7(7):2003–11. DOI: 10.1158/15357163.MCT-08-0095
13. Smith J.A., Wilson L., Azarenko O., Zhu X., Lewis B.M., Littlefield B.A., et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49(6):1331–7. DOI: 10.1021/bi901810u
14. Kenny L., Beresford M., Brown I., Misra V., Kristeleit H. Eribulin for the treatment of advanced breast cancer: A prospective observational registry study. Eur J Cancer Care (Engl). 2022;31(6):e13747. DOI: 10.1111/ecc.13747
15. Kashiwagi S., Asano Y., Goto W., Takada K., Morisaki T., Kouhashi R., et al. Validation of systemic and local tumour immune response to eribulin chemotherapy in the treatment of breast cancer. Anticancer Res. 2020;40(6):3345–54. DOI: 10.21873/anticanres.14317
16. Uemura D., Takahashi K., Yamamoto T., Katayama C., Tanaka J., Okumura Y., et al. Norhalichondrin A: An antitumor polyether macrolide from a marine sponge. J Am Chem Soc. 1985;107(16):4796–8. DOI: 10.1021/ja00302a042
17. Swami U., Chaudhary I., Ghalib M.H., Goel S. Eribulin — A review of preclinical and clinical studies. Crit Rev Oncol Hematol. 2012;81(2):163–84. DOI: 10.1016/j.critrevonc.2011.03.002
18. Donoghue M., Lemery S.J., Yuan W., He K., Sridhara R., Shord S., et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: Use of a “physician’s choice” control arm in a randomized approval trial. Clin Cancer Res. 2012;18(6):1496–505. DOI: 10.1158/1078-0432.CCR-11-2149.
19. Jordan M.A., Kamath K., Manna T., Okouneva T., Miller H.P., Davis C., et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4(7):1086–95. DOI: 10.1158/1535-7163.MCT-04-0345
20. Tan A.R., Rubin E.H., Walton D.C., Shuster D.E., Wong Y.N., Fang F., et al. Phase I study of eribulin mesylate administered once every days in patients with advanced solid tumors. Clin Cancer Res. 2009;15(12):4213–9. DOI: 10.1158/1078-0432.CCR-09-0360
21. de Nonneville A., Sabatier R., Gonçalves A., Extra J.M., Tarpin C., Launay S., et al. Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer. J Geriatr Oncol. 2018;9(3):281–3. DOI: 10.1016/j.jgo.2017.11.003
22. Fukada I., Ito Y., Kondo N., Ohtani S., Hattori M., Tokunaga E., et al. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17). Breast Cancer Res Treat. 2021;190(3):425– 34. DOI: 10.1007/s10549-021-06396-0
23. Towle M.J., Salvato K.A., Budrow J., Wels B.F., Kuznetsov G., Aalfs K.K., et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013– 21. PMID: 11221827
24. Aogi K., Iwata H., Masuda N., Mukai H., Yoshida M., Rai Y., et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012;23(6):1441–8. DOI: 10.1093/ annonc/mdr444
25. Cortes J., Vahdat L., Blum J.L., Twelves C., Campone M., Roché H., et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously reated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28(25):3922–8. DOI: 10.1200/JCO.2009.25.8467
26. Vahdat L.T., Pruitt B., Fabian C.J., Rivera R.R., Smith D.A., Tan-Chiu E., et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;27(18):2954–61. DOI: 10.1200/JCO.2008.17.7618
27. Cortes J., O'Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23. DOI: 10.1016/S0140-6736(11)60070-6
28. Twelves C., Cortes J., Vahdat L.T., Wanders J., Akerele C., Kaufman P.A. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010;10(2):160–3. DOI: 10.3816/CBC.2010.n.023
29. Greenhalgh J., Bagust A., Boland A., Oyee J., Trevor N., Beale S., et al. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal. Pharmacoeconomics. 2015;33(2):137–48. DOI: 10.1007/s40273-014-0214-2
30. Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Velikova G., et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601. DOI: 10.1200/JCO.2013.52.4892
31. Manso L., Moreno Antón F., Izarzugaza Perón Y., Delgado Mingorance J.I., Borrega García P., Echarri González M.J., et al. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. Breast J. 2019;25(2):219–25. DOI: 10.1111/tbj.13199
32. Sang D., Song L.H., Di L.J., Wang Y.L., Liu C.G., Guo Z.Q., et al. Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer. Zhonghua Zhong Liu Za Zhi. 2022;44(4):364–9. DOI: 10.3760/cma.j.cn112152-20210226-00173
33. Hayashida T., Jinno H., Mori K., Sato H., Matsui A., Sakurai T., et al. Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: a multicenter, singlearm trial. BMC Cancer. 2018;18(1):701. DOI: 10.1186/s12885-0184628-7
34. Yamashita T., Kawaguchi H., Masuda N., Kitada M., Narui K., Hattori M., et al. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). Invest New Drugs. 2021;39(1):217–25. DOI: 10.1007/s10637-020-00991-6
35. De Angelis C., Bruzzese D., Bernardo A., Baldini E., Leo L., Fabi A., et al. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open. 2021;6(2):100097. DOI: 10.1016/j.esmoop.2021.100054
36. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Female Breast Cancer Subtypes. [cited 2020 June 4]. Available from: https://seer.cancer.gov/statfacts/html/breastsubtypes.html
37. Mougalian S.S., Kish J.K., Zhang J., Liassou D., Feinberg B.A. Effectiveness of eribulin in metastatic breast cancer: 10 years of real-world clinical experience in the United States. Adv Ther. 2021;38(5):2213–25. DOI: 10.1007/s12325-020-01613-6
38. Filonenko D.V., Belonogov A.V. Eribulin mesylate: our experience in a real-life clinical setting. Malignant Tumours. 2017;7(4):21–8 (In Russ.). DOI: 10.18027/2224-5057-2017-7-4-21-28
39. Watanabe J., Ito Y., Ohsumi S., Mizutani M., Tashiro H., Sakurai K., et al. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing ob-servational study. Investig New Drugs. 2017;35:791–9. DOI: 10.1007/s10637-0170486-4
40. Maeda S., Saimura M., Minami S., Kurashita K., Nishimura R., Kai Y., et al. Efficacy and safety of eribulin as firstto third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Breast. 2017;32:66–72. DOI: 10.1016/j.breast.2016.12.017
41. Chen P.H., Yeh D.C., Tung H.H., Lin C.Y. Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer. Medicine (Baltimore). 2021;100(47):e27859. DOI: 10.1097/ MD.0000000000027859
42. Pivot X., Im S.A., Guo M., Marmé F. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer. 2018;25(3):370–4. DOI: 10.1007/s12282017-0826-4
43. Inoue K., Saito T., Okubo K., Kimizuka K., Yamada H., Sakurai T., et al. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance. Breast Cancer Res Treat. 2016;157:295–305. DOI: 10.1007/ s10549-016-3808-x
44. Watanabe J. Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review. Springerplus. 2015;4:625. DOI: 10.1186/ s40064-015-1422-8
45. Kikuchi Y., Uchida Y., Shirakawa K., Kanauchi H., Niwa T., Nishioka K., et al. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens. Asia Pac J Clin Oncol. 2018;14:e231–7. DOI: 10.1111/ajco.12863
46. Inoue K., Takahashi M., Mukai H., Yamanaka T., Egawa C., Sakata Y., et al. Effectiveness and safety of eribulin in Japanese patients with HER2negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Invest New Drugs. 2020;38(5):1540–9. DOI: 10.1007/s10637-019-00890-5
Review
For citations:
Sultanbaev A.V., Menshikov K.V., Musin Sh.I., Menshikova I.A., Sultanbaeva N.I., Popova E.V., Askarov V.E. Eribulin in Metastatic Breast Cancer: Actual Clinical Practice. Creative surgery and oncology. 2023;13(1):77-86. (In Russ.) https://doi.org/10.24060/2076-3093-2023-13-1-77-86
Views:
2224
Email this article 